Literature DB >> 3122218

Cloning of the chromosome translocation breakpoint junction of the t(14;19) in chronic lymphocytic leukemia.

T W McKeithan1, J D Rowley, T B Shows, M O Diaz.   

Abstract

Our laboratory has reported that t(14;19)(q32; q13.1) is a recurring translocation in the neoplastic cells of patients with chronic lymphocytic leukemia. In the present study, we have analyzed the leukemic cells from one such patient with probes from the immunoglobulin heavy-chain locus, which is present on band q32 of chromosome 14. Using a probe for the alpha constant-region gene segments, we detected a rearranged band by Southern blot analysis. This rearranged band was cloned and mapped. A subclone free of repetitive sequences was shown to be from chromosome 19 by analysis of human-mouse somatic cell hybrids, confirming that the rearranged band contains the translocation breakpoint junction. This probe may be used to identify a gene on chromosome 19 adjacent to the breakpoint that can contribute to the malignant development of B lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3122218      PMCID: PMC299732          DOI: 10.1073/pnas.84.24.9257

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  22 in total

1.  Cloning and sequencing of a c-myc oncogene in a Burkitt's lymphoma cell line that is translocated to a germ line alpha switch region.

Authors:  L C Showe; M Ballantine; K Nishikura; J Erikson; H Kaji; C M Croce
Journal:  Mol Cell Biol       Date:  1985-03       Impact factor: 4.272

2.  Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation.

Authors:  Y Tsujimoto; L R Finger; J Yunis; P C Nowell; C M Croce
Journal:  Science       Date:  1984-11-30       Impact factor: 47.728

3.  Prognostic significance of chromosome abnormalities in chronic lymphocytic leukaemia.

Authors:  S Pittman; D Catovsky
Journal:  Br J Haematol       Date:  1984-12       Impact factor: 6.998

4.  Differential expression of the translocated and the untranslocated c-myc oncogene in Burkitt lymphoma.

Authors:  A ar-Rushdi; K Nishikura; J Erikson; R Watt; G Rovera; C M Croce
Journal:  Science       Date:  1983-10-28       Impact factor: 47.728

5.  Genomic sequencing.

Authors:  G M Church; W Gilbert
Journal:  Proc Natl Acad Sci U S A       Date:  1984-04       Impact factor: 11.205

6.  Human immunoglobulin heavy chain A2 gene allotype determination by restriction fragment length polymorphism.

Authors:  M P Lefranc; T H Rabbitts
Journal:  Nucleic Acids Res       Date:  1984-02-10       Impact factor: 16.971

7.  Nonrandom chromosome abnormalities in lymphoma.

Authors:  C D Bloomfield; D C Arthur; G Frizzera; E G Levine; B A Peterson; K J Gajl-Peczalska
Journal:  Cancer Res       Date:  1983-06       Impact factor: 12.701

8.  The human c-myc oncogene: structural consequences of translocation into the IgH locus in Burkitt lymphoma.

Authors:  J Battey; C Moulding; R Taub; W Murphy; T Stewart; H Potter; G Lenoir; P Leder
Journal:  Cell       Date:  1983-10       Impact factor: 41.582

9.  Interleukin 2 (IL2) is assigned to human chromosome 4.

Authors:  T Shows; R Eddy; L Haley; M Byers; M Henry; T Fujita; H Matsui; T Taniguchi
Journal:  Somat Cell Mol Genet       Date:  1984-05

Review 10.  Translocations among antibody genes in human cancer.

Authors:  P Leder; J Battey; G Lenoir; C Moulding; W Murphy; H Potter; T Stewart; R Taub
Journal:  Science       Date:  1983-11-18       Impact factor: 47.728

View more
  25 in total

1.  The putative oncoprotein Bcl-3 induces cyclin D1 to stimulate G(1) transition.

Authors:  S D Westerheide; M W Mayo; V Anest; J L Hanson; A S Baldwin
Journal:  Mol Cell Biol       Date:  2001-12       Impact factor: 4.272

Review 2.  Molecular biology in medicine.

Authors:  B D Young
Journal:  Postgrad Med J       Date:  1992-04       Impact factor: 2.401

3.  The repressing function of the oncoprotein BCL-3 requires CtBP, while its polyubiquitination and degradation involve the E3 ligase TBLR1.

Authors:  Aurore Keutgens; Kateryna Shostak; Pierre Close; Xin Zhang; Benoît Hennuy; Marie Aussems; Jean-Paul Chapelle; Patrick Viatour; André Gothot; Marianne Fillet; Alain Chariot
Journal:  Mol Cell Biol       Date:  2010-06-14       Impact factor: 4.272

4.  The physical map of chromosome arm 19q: some new assignments, confirmations and re-assessments.

Authors:  J D Brook; S J Knight; S H Roberts; H G Harley; K V Walsh; S A Rundle; K Freyne; M C Koch; N D Epstein; B Wieringa
Journal:  Hum Genet       Date:  1991-05       Impact factor: 4.132

5.  Localisation of the myotonic dystrophy locus to 19q13.2-19q13.3 and its relationship to twelve polymorphic loci on 19q.

Authors:  H G Harley; K V Walsh; S Rundle; J D Brook; M Sarfarazi; M C Koch; J L Floyd; P S Harper; D J Shaw
Journal:  Hum Genet       Date:  1991-05       Impact factor: 4.132

6.  Expression of the Bcl-3 proto-oncogene suppresses p53 activation.

Authors:  David Kashatus; Patricia Cogswell; Albert S Baldwin
Journal:  Genes Dev       Date:  2005-12-29       Impact factor: 11.361

7.  Constitutive expression of Bc1-3 in thymocytes increases the DNA binding of NF-kappaB1 (p50) homodimers in vivo.

Authors:  J H Caamaño; P Perez; S A Lira; R Bravo
Journal:  Mol Cell Biol       Date:  1996-04       Impact factor: 4.272

8.  CD8 T cells require Bcl-3 for maximal gamma interferon production upon secondary exposure to antigen.

Authors:  Paula M Chilton; Thomas C Mitchell
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

Review 9.  Reappraisal of BCL3 as a molecular marker of anaplastic large cell lymphoma.

Authors:  Hitoshi Ohno; Momoko Nishikori; Yoshitomo Maesako; Hironori Haga
Journal:  Int J Hematol       Date:  2005-12       Impact factor: 2.490

10.  The proto-oncogene Bcl3, induced by Tax, represses Tax-mediated transcription via p300 displacement from the human T-cell leukemia virus type 1 promoter.

Authors:  Young-Mi Kim; Neelam Sharma; Jennifer K Nyborg
Journal:  J Virol       Date:  2008-09-24       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.